Cynthia E. Schairer, PhD, Caryn Kseniya Rubanovich, MS, and Cinnamon S. Bloss, PhD
Questions about data privacy need to be addressed when research institutions negotiate with companies developing mobile health applications. Commercial terms of use and data sharing notifications should be reviewed before use in human subject research settings.
AMA J Ethics. 2018;20(9):E864-872. doi:
10.1001/amajethics.2018.864.
Carly P. Smith, PhD and Daniel R. George, PhD, MSc
Invisibility of racial inequity and gender inclusion in clinical research means key features of disease etiology and symptom presentation are unaccounted for.
AMA J Ethics. 2021;23(7):E563-568. doi:
10.1001/amajethics.2021.563.
Introduction of an intervention that reduces the perceived risk of a given behavior may cause a person to increase risky behavior—this is called “risk compensation.”
Bias toward allopathic medicine in the research funding and publication of study results makes it difficult for physicians and others to find accurate data about the efficacy of non-Western, nonallopathic treatments.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
Analysis of three studies that say medical students and residents are more comfortable communicating and treating patients who differ from them after international electives and cultural sensitivity training.